Targeting the Epigenome for the Treatment of Thoracic Malignancies

Thoracic Surgery Clinics

Volumn 16, Issue 4, 2006, Pages 367-377

  Schrump, David S ^a   Nguyen, Dao M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FLAVOPIRIDOL; FR 901228; HISTONE DEACETYLASE INHIBITOR;

CANCER PATIENT; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG MECHANISM; EPIGENETICS; GENE EXPRESSION; HUMAN; LUNG CANCER; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; THORAX DISEASE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; DEPSIPEPTIDES; DRUG EVALUATION, PRECLINICAL; EPIGENESIS, GENETIC; HUMANS; LUNG NEOPLASMS;

EID: 37849189063     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2006.07.005     Document Type: Review

References (67)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Schrump D.S., Altorki N.K., Henschke C.I., et al. Nonsmall cell lung cancer. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles & practice of oncology. 7th edition (2005), Lippincott Williams & Wilkins, Philadelphia 753-810
3. Peto R. Influence of dose and duration of smoking on lung cancer rates. In: Zaridze D, Peto R, editors. Tobacco: a major international health hazard. Proceedings of an internal meeting, Moscow, USSR, June 4-6, 1985. International Agency for Research on Cancer Science Publication No. 74. Lyon (France): World Health Organization, International Agency for Research on Cancer; 1986. p. 23-33.
4. Peto R., Darby S., Deo H., et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 321 (2000) 323-329
5. Alberg A.J., Brock M.V., and Samet J.M. Epidemiology of lung cancer: looking to the future. J Clin Oncol 23 (2005) 3175-3185
6. Mulshine J.L. New developments in lung cancer screening. J Clin Oncol 23 (2005) 3198-3202
7. Hirsch F.R., and Lippman S.M. Advances in the biology of lung cancer chemoprevention. J Clin Oncol 23 (2005) 3186-3197
8. Meyerson M., and Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 23 (2005) 3219-3226
9. Schrump D.S., and Nguyen D.M. Targets for molecular intervention in multistep pulmonary carcinogenesis. World J Surg 25 (2001) 174-183
10. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 94 (2006) 179-183
11. Weinhold B. Epigenetics: the science of change. Environ Health Perspect 114 (2006) A160-A167
12. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 3 (2002) 662-673
13. Jaenisch R., and Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33 (2003) 245-254
14. Khan A.U., and Krishnamurthy S. Histone modifications as key regulators of transcription. Front Biosci 10 (2005) 866-872
15. Hermann A., Gowher H., and Jeltsch A. Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 61 (2004) 2571-2587
16. Jones P.A. The DNA methylation paradox. Trends Genet 15 (1999) 34-37
17. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 15 (2005) 490-495
18. Wang Y., Wysocka J., Perlin J.R., et al. Linking covalent histone modifications to epigenetics: the rigidity and plasticity of the marks. Cold Spring Harb Symp Quant Biol 69 (2004) 161-169
19. Kouzarides T. Wellcome Trust Award Lecture. Chromatin-modifying enzymes in transcription and cancer. Biochem Soc Trans 31 (2003) 741-743
20. Jones P.A., and Takai D. The role of DNA methylation in mammalian epigenetics. Science 293 (2001) 1068-1070
21. Cameron E.E., Bachman K.E., Myohanen S., et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21 (1999) 103-107
22. Schrump D.S., and Nguyen D.M. Targeting the epigenome for the treatment and prevention of lung cancer. Semin Oncol 32 (2005) 488-502
23. Fraga M.F., and Esteller M. Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle 4 (2005) 1377-1381
24. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 45 (2005) 629-656
25. Hong J.A., Kang Y., Abdullaev Z., et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65 (2005) 7763-7774
26. Vatolin S., Abdullaev Z., Pack S.D., et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65 (2005) 7751-7762
27. Suri A. Cancer testis antigens-their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther 6 (2006) 379-389
28. Herman J.G. Epigenetics in lung cancer: focus on progression and early lesions. Chest 125 (2004) 119S-122S
29. Toyooka S., Maruyama R., Toyooka K.O., et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103 (2003) 153-160
30. Schrump D.S. Modulation of DNA methylation for the treatment and prevention of cCancer. In: Kelloff G.J., Hawk E., and Sigman C. (Eds). Cancer chemoprevention, vol. 1: Promising cancer chemoprevention agents (2004), Humana Press, Totowa (NJ) 643-658
31. Lyko F., and Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97 (2005) 1498-1506
32. Gowher H., and Jeltsch A. Mechanism of inhibition of DNA methyltransfers by cytidine analogs in cancer therapy. Cancer Biol Ther 3 (2004) 1062-1068
33. Steiner F., Hong J., Fischette M., et al. Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 24 (2005) 2386-2397
34. Atanackovic D., Altorki N.K., Stockert E., et al. Vaccine-induced CD4 + T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172 (2004) 3289-3296
35. *04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 27 (2004) 472-477
36. Stockert E., Jäger E., Chen Y.-T., et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187 (1998) 1349-1354
37. Sharma S., Stolina M., Yang S.C., et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 9 (2003) 961-968
38. Wolf A.M., Wolf D., Steurer M., et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9 (2003) 606-612
39. Ballestar E., and Esteller M. The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications. Prog Mol. Subcell Biol 38 (2005) 169-181
40. INK4 gene mediated by an adenovirus vector. Cancer Res 55 (1995) 3250-3253
41. Weiser T.S., Guo Z.S., Ohnmacht G.A., et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 24 (2001) 151-161
42. Weiser T.S., Ohnmacht G.A., Guo Z.S., et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 71 (2001) 295-301
43. Restifo N.P., Esquivel F., Kawakami Y., et al. Identification of human cancers deficient in antigen processing. J Exp Med 177 (1993) 265-272
44. Guo Z.S., Hong J.A., Irvine K.R., et al. De novo iInduction of a cancer/testis antigen by 5-Aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 66 (2006) 1105-1113
45. Brandle D., Bilsborough J., Rulicke T., et al. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur J Immunol 28 (1998) 4010-4019
46. Kassis E.M., Zhao M., Hong J.A., et al. Depletion of DNA methyltransferase (DNMT)1, and/or DNMT3b mediates growth arrest and apoptosis in cultured thoracic malignancies. J Thorac Cardiovasc Surg 131 (2006) 298-306
47. Milutinovic S., Zhuang Q., Niveleau A., et al. Epigenomic stress response. Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes. J Biol Chem 278 (2003) 14985-14995
48. Juttermann R., Li E., and Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 91 (1994) 11797-11801
49. Nguyen D.M., Schrump W.D., Chen G.A., et al. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 10 (2004) 1813-1825
50. Yu X., Guo Z.S., Marcu M.G., et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94 (2002) 504-513
51. Neckers L., Schulte T.W., and Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 17 (1999) 361-373
52. Yu X, Yang Y, Chen GA, et al. Apoptosis induced by depsipeptide FK228 coincides with inhibition of EGFR-mediated survival signaling in lung cancer cells. Lung Cancer, in press.
53. Schrump D.S., Matthews W., Chen G.A., et al. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res 4 (1998) 2885-2890
54. Schrump D.S., and Waheed I. Strategies to circumvent SV40 oncoprotein expression in malignant pleural mesotheliomas. Semin Cancer Biol 11 (2001) 73-80
55. Schrump D.S., and Nguyen D.M. Strategies for molecular intervention in esophageal cancers and their precursor lesions. Dis Esophagus 12 (1999) 181-185
56. Nguyen D.M., Schrump W.D., Tsai W.S., et al. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway. J Thorac Cardiovasc Surg 125 (2003) 1132-1142
57. Gartel A.L., and Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1 (2002) 639-649
58. Rebbaa A, Zheng X, Chu F, et al. The role of histone acetylation versus DNA damage in drug-induced senescence and apoptosis. Cell Death Differ, in press.
59. Shapiro G.I., Supko J.G., Patterson A., et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7 (2001) 1590-1599
60. Krysan K., Reckamp K.L., Dalwadi H., et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65 (2005) 6275-6281
61. Dannenberg A.J., and Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4 (2003) 431-436
62. Riedl K., Krysan K., Pold M., et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 7 (2004) 169-184
63. Altorki N.K., Keresztes R.S., Port J.L., et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21 (2003) 2645-2650
64. Sharma S., Yang S.C., Zhu L., et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4 + CD25 + T regulatory cell activities in lung cancer. Cancer Res 65 (2005) 5211-5220
65. Sharma S., Zhu L., Yang S.C., et al. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol 175 (2005) 813-819
66. Zeytin H.E., Patel A.C., Rogers C.J., et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res 64 (2004) 3668-3678
67. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89